

Status of the Claims

Claims 1, 2 and 4 have been amended.

Claims 3, 5-9 and 14-23 have been withdrawn.

Claims 12 and 13 have been canceled.

Claim 24 is new.

Restriction Requirement

Claims 1, 2 and 4 have been amended and Claims 3, 5-9 and 14-23 have been withdrawn in order to remove unelected subject matter.

Rejection pursuant to 35 USC § 112, first paragraph

Claims 12 and 13 are rejected under 35 USC § 112, first paragraph, as failing to comply with the enablement requirement. In view of the cancellation of Claims 12 and 13 it is believed that the rejection has been rendered moot.

New Claim


Claim 24 is new. Support for the new claim can be found in examples 1A-1, 2A-1, 2A-2, 2A-3, 2A-4, 3A-1 and 4A-1.

Conclusion

It is believed that the Claims are in condition for allowance, and it is respectfully requested that the application be passed to issue.

If the Examiner believes a telephonic interview with Applicants' representative would aid in the prosecution of this application, he is cordially invited to contact Applicants' representative at the below listed number.

Respectfully submitted,



Julie M. Lappin, Reg. No. 46,612

Pharmacia Corporation
of Pfizer, Inc.
P.O. Box 1027
Chesterfield, MO 63006
(314) 274-2009
(314) 274-9095 (facsimile)